Total Payments
$82,111
2024 Payments
$206.73
Companies
11
Transactions
65
Medicare Patients
936
Medicare Billing
$209,867
Payment Breakdown by Category
Consulting$49,307 (60.0%)
Other$18,871 (23.0%)
Research$12,544 (15.3%)
Food & Beverage$829.59 (1.0%)
Travel$559.43 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $49,307 | 19 | 60.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,871 | 21 | 23.0% |
| Unspecified | $12,544 | 8 | 15.3% |
| Food and Beverage | $829.59 | 14 | 1.0% |
| Travel and Lodging | $559.43 | 3 | 0.7% |
Payments by Type
General
$69,567
57 transactions
Research
$12,544
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $36,080 | 27 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $10,599 | 5 | $0 (2019) |
| Genentech, Inc. | $9,660 | 9 | $0 (2021) |
| F. Hoffmann-La Roche AG | $5,298 | 3 | $0 (2020) |
| PFIZER INC. | $4,354 | 2 | $0 (2022) |
| Janssen Global Services, LLC | $3,310 | 2 | $0 (2020) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $3,284 | 12 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,220 | 1 | $0 (2018) |
| AstraZeneca UK Limited | $2,758 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,555 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $206.73 | 2 | AstraZeneca Pharmaceuticals LP ($206.73) |
| 2022 | $1,184 | 2 | PFIZER INC. ($1,166) |
| 2021 | $12,210 | 6 | AstraZeneca Pharmaceuticals LP ($4,110) |
| 2020 | $20,142 | 10 | AstraZeneca Pharmaceuticals LP ($10,715) |
| 2019 | $12,436 | 12 | AstraZeneca Pharmaceuticals LP ($9,725) |
| 2018 | $27,357 | 18 | AstraZeneca Pharmaceuticals LP ($11,323) |
| 2017 | $8,574 | 15 | Boehringer Ingelheim Pharma GmbH & Co.KG ($3,284) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $106.73 | General |
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Oncology | ||||||
| 07/08/2022 | AstraZeneca UK Limited | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Oncology | ||||||
| 03/18/2022 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,166.00 | General |
| 10/01/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| 05/31/2021 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Consulting Fee | Cash or cash equivalent | $2,555.00 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| 05/13/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 05/04/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| Category: Oncology | ||||||
| 03/18/2021 | AstraZeneca UK Limited | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/26/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $4,450.00 | General |
| Category: Oncology | ||||||
| 11/26/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 08/06/2020 | Genentech, Inc. | — | — | Cash or cash equivalent | $990.00 | Research |
| Study: ATEZOLIZUMAB CARBOPLATIN ETOPOSIDE TIRAGOLUMAB OR PLACEBO IN 1L ES SCLC | ||||||
| 07/20/2020 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,760.00 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $4,696.81 | Research |
| Study: A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB MPDL3280A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES • Category: BioOncology | ||||||
| 06/15/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 05/27/2020 | Genentech, Inc. | — | — | Cash or cash equivalent | $1,980.00 | Research |
| Study: ATEZOLIZUMAB CARBOPLATIN ETOPOSIDE TIRAGOLUMAB OR PLACEBO IN 1L ES SCLC | ||||||
| 03/29/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 02/25/2020 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.34 | General |
| 02/18/2020 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $72.73 | General |
| 11/05/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| Category: Oncology | ||||||
| 11/05/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $249.17 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $181.26 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $129.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB MPDL3280A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES | F. Hoffmann-La Roche AG | $4,697 | 1 |
| 1L SCLC ED | Genentech, Inc. | $3,885 | 4 |
| ATEZOLIZUMAB CARBOPLATIN ETOPOSIDE TIRAGOLUMAB OR PLACEBO IN 1L ES SCLC | Genentech, Inc. | $2,970 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $992.11 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 240 | 507 | $282,945 | $55,640 |
| 2022 | 4 | 211 | 460 | $258,770 | $52,005 |
| 2021 | 3 | 180 | 402 | $206,265 | $49,447 |
| 2020 | 7 | 305 | 591 | $246,814 | $52,776 |
Total Patients
936
Total Services
1,960
Medicare Billing
$209,867
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 101 | 236 | $146,418 | $27,850 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 80 | $60,968 | $12,225 | 20.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 60 | $27,714 | $6,045 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 44 | $18,007 | $3,487 | 19.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 27 | 36 | $14,528 | $2,720 | 18.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 36 | $10,480 | $2,278 | 21.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 15 | 15 | $4,830 | $1,036 | 21.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 90 | 220 | $133,906 | $26,355 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 76 | $56,318 | $11,703 | 20.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 63 | $25,641 | $5,578 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 32 | 47 | $18,717 | $3,706 | 19.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 30 | 34 | $13,540 | $2,513 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 20 | $10,648 | $2,150 | 20.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 82 | 238 | $123,798 | $29,233 | 23.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 28 | 78 | $49,695 | $12,573 | 25.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 35 | 42 | $14,124 | $3,404 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 23 | 26 | $10,233 | $2,138 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 18 | $8,415 | $2,099 | 24.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 83 | 191 | $95,870 | $18,179 | 19.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 35 | 117 | $49,245 | $10,857 | 22.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 53 | 102 | $33,870 | $7,022 | 20.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 26 | 53 | $31,745 | $6,845 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 50 | 59 | $11,055 | $4,081 | 36.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $9,747 | $2,166 | 22.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 17 | $7,636 | $1,577 | 20.7% |
About Dr. Lecia Sequist, MD
Dr. Lecia Sequist, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417948316.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lecia Sequist, MD has received a total of $82,111 in payments from pharmaceutical and medical device companies, with $206.73 received in 2024. These payments were reported across 65 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($49,307).
As a Medicare-enrolled provider, Sequist has provided services to 936 Medicare beneficiaries, totaling 1,960 services with total Medicare billing of $209,867. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Boston, MA
- Active Since 10/31/2005
- Last Updated 12/24/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1417948316
Products in Payments
- TAGRISSO (Drug) $35,112
- GILOTRIF (Drug) $17,103
- Tecentriq (Biological) $4,697
- TECENTRIQ (Biological) $4,487
- IMFINZI (Drug) $3,519
- ALUNBRIG (Drug) $2,555
- LUMINESPIB (Drug) $992.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M